The U.S. Supreme Court has agreed to hear a case that could dismantle thousands of state-level lawsuits alleging that Bayer's Roundup herbicide causes cancer. At issue is whether federal pesticide labeling laws preempt failure-to-warn claims under state tort law—a question that will determine the legal liability of one of the most widely used weedkillers in the world.
Nearly 4,000 plaintiffs, including John Durnell of St. Louis, say that decades of Roundup exposure led to non-Hodgkin lymphoma and other blood cancers. Durnell, who used the product for routine yard work, underwent multiple rounds of chemotherapy. The central scientific dispute revolves around glyphosate, Roundup's active ingredient, which the International Agency for Research on Cancer classified as "probably carcinogenic to humans" in 2015. No specific emissions or percentage reduction figures were provided in the source.
Bayer, which acquired Roundup through its $63 billion purchase of Monsanto in 2018, has already settled roughly 100,000 claims for nearly $11 billion but faces ongoing litigation. The company argues that the Environmental Protection Agency's approval of glyphosate should shield it from state-level verdicts. Investors are watching closely: Bayer shares have fallen sharply since the acquisition, and an adverse ruling could open the door to tens of thousands of new claims. No exact job or market size figures were cited.
The case arrives as the conservative-leaning Court limits corporate liability in other product-safety contexts. A decision for Bayer would effectively end most pending Roundup lawsuits, while a ruling for plaintiffs could trigger a cascade of state-level trials. The outcome carries implications for global pesticide regulation and trade, as the EPA's stance on glyphosate diverges from stricter European Union policies. The Paris Agreement was not mentioned in the source.
Consumer advocacy groups warn that a preemption ruling would strip individuals of their day in court against chemical manufacturers. "If the Supreme Court sides with Bayer, it means companies can ignore state warning requirements and leave the public in the dark," one legal analyst noted. The Court is expected to hear oral arguments in the fall.